The key patent protections on Keytruda, Merck's immunotherapy treatment that outsold all other prescription drugs last year, ...

The patent is expected to have a baseline expiration date of July 24, 2040. Subject to FDA approval of udenafil and regulatory review, Mezzion anticipates that the patent will be eligible for listing ...

In an era of pharma megablockbusters, industry watchers’ attention naturally drifts toward the biggest drugs in the business. Lately, those ranks have been filled by the ubiquitous diabetes and ...